NEI Research News

Progression along an age-related macular degeneration (AMD) severity scale over two years predicts the likelihood of developing late-stage disease five years later.

Babies born prematurely who require treatment to prevent blindness from retinopathy of prematurity (ROP) could be treated with a dose of Avastin (bevacizumab) that is a fraction of the dose commonly used for ROP currently.

According to a recent analysis of data from two major eye disease studies, adherence to the Mediterranean diet – high in vegetables, whole grains, fish, and olive oil – correlates with higher cognitive function.

In 2017, approximately 93 million US adults aged 18 years or older, or about 4 in 10, were at high risk for vision loss, according to a new study published in JAMA Ophthalmology.

An artificial intelligence (AI) device that has been fast-tracked for approval by the Food and Drug Administration may help identify newborns at risk for aggressive posterior retinopathy of prematurity (AP-ROP). AP-ROP is the most severe form of ROP.

According to a study from Emory University, as young as six days a baby’s brain appears hardwired for the specialized tasks of seeing faces and seeing places.

Missing a single ophthalmology appointment over a two-year period was associated with decreased visual acuity for patients with macular degeneration according to a new Penn Medicine study.

A new study from Brown researchers finds that rewards improve performance on a visual perceptual task only if participants sleep after training.

Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy, the advanced “dry” form of age-related macular degeneration.

Results from a clinical trial funded by the National Eye Institute (NEI) show that while vision therapy can successfully treat convergence insufficiency (CI) in children, it fails to improve their reading test scores.